Radius Health Inc logo

RDUS - Radius Health Inc News Story

$11.55 0.2  1.9%

Last Trade - 01/10/20

Mid Cap
Market Cap £408.0m
Enterprise Value £476.6m
Revenue £155.2m
Position in Universe 2880th / 6413

BUZZ-Radius Health: Rises on license deal for breast cancer treatment

Fri 24th July, 2020 4:40pm
** Drug maker's shares  RDUS.O  rise 7.7% to $13.70 
    ** Co said after market on Thursday that privately held
Menarini Group has signed a global license agreement to develop
and commercialize RDUS's investigational therapy, elacestrant,
to treat advanced HER2-breast cancer  urn:newsml:reuters.com:*:nGNXbq4QjT
    ** RDUS will get an upfront payment of $30 million and up to
$320 million in milestone payments
    ** Menarini Group will be responsible for worldwide
commercialization of elacestrant - RDUS
    ** The treatment is currently being evaluated in a
late-stage study 
    ** Including session's gains, stock has fallen 32% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.